This study addresses a critical gap by investigating whether MSH2 modulates Wnt activity to foster glioma stemness and chemoresistance, thereby offering insights into dual‐targeted strategies to disrupt the GSC niche and overcome therapeutic resistance, ultimately improving clinical outcomes. Here, MSH2 is linked to glioma.